Furthermore, intravenous glutathione (12 injections of 1,200 mg) showed no benefit for skin lightening compared to placebo in a Pakistani study (Zubair et al., J Pakistan Assoc Dermatol, 2016) [64]
10.1016/j.neuron.2004.09.012 89 MarikS
GLP-1 utilization and spending are expected to continue growing as more prescribers and patients embrace the popular injectable formulations of these treatments, and, while the oral option may attract patients previously hesitant to try GLP-1 therapies due to injection concerns, it is unlikely to surpass injectables in market share
In indirect comparisons, oral semaglutide at 25 mg produced roughly 14% weight loss, while Rybelsus at 14 mg has been associated with approximately 5% weight loss in diabetes trials
The ability to even file an ANDA is subject to applicable FDA exclusivity periods
Heres where the frequency matters